Caissa Capital Management ltd. - 07 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
07 Jun 2023
Net transactions value
+$56,440
Form type
4
Filing time
09 Jun 2023, 16:24:16 UTC
Previous filing
02 Jun 2023
Next filing
14 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $10,418 +2,984 +0.22% $3.49* 1,389,199 07 Jun 2023 See Footnote (1) F1, F2
transaction AVTX Common Stock Purchase $25,126 +6,398 +0.46% $3.93* 1,395,597 08 Jun 2023 See Footnote (1) F1, F3
transaction AVTX Common Stock Purchase $20,896 +5,044 +0.36% $4.14* 1,400,641 09 Jun 2023 See Footnote (1) F1, F4
holding AVTX Common Stock 182,300 07 Jun 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.6, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $4.22, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.3, inclusive.
F5 These shares are directly owned by Mr. Golestaneh in his personal capacity.